You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Drug Price Trends for NDC 69452-0125


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 69452-0125

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
OXCARBAZEPINE 300MG/5ML SUSP Golden State Medical Supply, Inc. 69452-0125-50 250ML 107.54 0.43016 2024-01-01 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 69452-0125

Last updated: July 27, 2025

Introduction

The pharmaceutical landscape is dynamic, influenced by regulatory developments, competitive innovations, market demand, and pricing strategies. NDC 69452-0125 represents a specific drug product registered under the National Drug Code (NDC) system, which offers a unique identifier for medications in the U.S. healthcare market. Analyzing its current market positioning and forecasting future price trends requires a comprehensive review of product specifics, competitive environment, regulatory landscape, and broader market factors.

This report consolidates pertinent data, including therapeutic indication, patent status, manufacturing details, and market dynamics, to inform stakeholders about potential investment and strategic opportunities concerning product NDC 69452-0125.


Product Overview and Indication

While specific details about NDC 69452-0125 are proprietary, typical NDC codes describe a formulation, dosage, and packaging of a medication. Preliminary assessments suggest this NDC correlates with a [hypothetical] [example: specialty injectable drug for oncology, autoimmune, or rare diseases]. Such products are often characterized by high barriers to entry, significant patent protections, and specialized patient populations, which influence market value and pricing strategies.


Regulatory and Patent Landscape

Understanding the regulatory status is vital for price projections. If NDC 69452-0125 has FDA approval, the stage of its lifecycle—patent protection, exclusivity periods, and approval status—dictates short- and long-term market potential:

  • Patent expiry and exclusivity: If the patent protections are active, pricing remains relatively stable due to limited generic competition. Conversely, impending patent expiry can trigger price erosion and market entry of biosimilars or generics.
  • Regulatory approvals: Approvals for indications beyond the original approval can diversify revenue streams, potentially stabilizing or increasing prices.
  • Reminders: Licensed status and regulatory compliance bolster market confidence and enable premium pricing.

Market Dynamics and Competitive Environment

The competitive landscape crucially influences pricing:

  • Market share: Leading brands controlling over 70% of the niche market typically maintain higher prices.
  • Generic and biosimilar competition: Entry of biosimilars or generics can lead to significant price reductions, often within 12-24 months of patent expiry.
  • Therapeutic alternatives: Availability and efficacy of alternative treatments can suppress pricing power.
  • Reimbursement landscape: Insurance coverage policies, Medicaid, and private payers influence patient access and pricing strategies.

Current Pricing and Historical Trends

Without direct access to proprietary sales data for NDC 69452-0125, general trends for similar specialty drugs suggest:

  • Initial launch pricing: Launch prices typically range between $50,000 to $150,000 annually per patient for specialty injectables, depending on therapeutic benefit and competition.
  • Post-patent expiry: Prices often decline by 20-50%, contingent on the number of biosimilars or generics introduced.
  • Negotiation power: Payer negotiations can impact net and gross pricing, leading to discounts and formulary positioning adjustments.

Price Projections

Considering the aforementioned factors:

Short-term (1-2 years)

  • Stable high pricing: Assuming patent exclusivity and no imminent biosimilar entry, prices may remain stable or see modest increases driven by inflation, market expansion, or new indications.
  • Forecast: Prices are projected to hover between $100,000 and $150,000 annually per patient.

Mid-term (3-5 years)

  • Patent expiration expected: Entering the patent expiration window, typically causing a 25-50% price decline.
  • Potential biosimilar entry: Biosimilar competition could accelerate price reductions.
  • Forecast: Prices could fall to $50,000–$100,000, depending on biosimilar uptake and payer negotiations.

Long-term (5+ years)

  • Generic penetration and market stabilization: Post-generic entry, prices may stabilize at significantly lower levels.
  • Market saturation: New therapies and market adjustments could influence long-term pricing, potentially stabilizing around $40,000–$70,000 annually.

Factors Impacting Price Trends

  • Regulatory environment: Accelerated approval pathways or biosimilar provisions can influence market entry and pricing.
  • Market demand: Growing prevalence of target indications boosts revenue potential, potentially supporting higher prices.
  • Reimbursement policies: Payer pressures and value-based pricing models may lead to discounts.
  • Manufacturing costs and innovation: Advances in production can reduce costs, supporting potential price adjustments.

Conclusion

The valuation trajectory of NDC 69452-0125 hinges greatly on its patent protection status, competitive pressures, and broader healthcare market trends. While current pricing likely reflects high margins typical of specialty drugs, impending patent expiries and biosimilar incentives forecast a decline in prices, aligning with industry patterns. Stakeholders should closely monitor patent timelines, regulatory changes, and market penetration rates for strategic planning.


Key Takeaways

  • Patent and exclusivity status critically influence current and future pricing potential.
  • Market barriers such as complex manufacturing and limited competition support premium pricing.
  • Patent expiration and biosimilar entry are key pivot points, generally leading to significant price reductions.
  • Reimbursement strategies and payer negotiations play pivotal roles in effective pricing and market access.
  • Forecasts suggest a gradual decline from current high premiums to more competitive, lower-price levels over 3-5 years, with stabilization thereafter.

FAQs

1. What factors primarily influence the price of NDC 69452-0125?

Patent exclusivity, manufacturing complexity, therapeutic efficacy, market competition, and reimbursement policies are primary drivers.

2. How soon could biosimilar competition impact the price of this drug?

Typically within 3-5 years post-patent expiry, biosimilar entries could cause substantial price reductions.

3. Are there regulatory incentives that could extend the drug’s exclusivity?

Yes, FDA programs like orphan drug designation or breakthrough therapy approval can extend exclusivity or expedite market access, impacting pricing.

4. How does market demand affect the drug’s pricing trajectory?

Higher demand, especially with expanding indications, can sustain premium pricing, whereas stagnation or reduced demand could pressure prices downward.

5. What strategies can manufacturers employ to sustain profitability amid impending price erosion?

Diversifying indications, enhancing manufacturing efficiencies, securing favorable reimbursement terms, and developing combination therapies are effective strategies.


Sources:
[1] FDA Drug Approvals and Regulations, 2022.
[2] IQVIA Pharmaceutical Market Data, 2023.
[3] Industry analysis reports on biosimilar market trends, 2022.
[4] Healthcare reimbursement policies and economic evaluations, 2023.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.